clinical trial · NCT07238062
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
Hope Biosciences Research Foundation·—·available
Multiple System AtrophyHB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
brief summary
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass pre-screening and a completed screening. The subjects will receive 12 intravenous infusions of HB-adMSCs and 6 intrathecal injections of HB-adMSCs over the course of 44 weeks (1 infusion each month and 1 injection every other month).
started
—
primary completion
—
completion
—
last updated
Apr 17, 2026
official title
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy."
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol